Figure 7
![Figure 7. Inhibition of NF-κB sensitizes BCR-ABL1–transformed B lymphoblasts to TKIs. (A) BCR-ABL1/GFP– or BCR-ABL1/IκBαSR–transformed primary B-lymphoid progenitors (4 × 104 cells per well) were incubated with different concentration of imatinib as indicated. Cell viability was determined by MTS assay after 96 hours’ incubation. (B-C) Equal numbers of primary B-lymphoid progenitors transformed by BCR-ABL1/GFP, BCR-ABL1/IKKαKM, or BCR-ABL1/IKKβKM were incubated with different concentration of imatinib (B) or dasatinib (C) as indicated. Cell viability was determined by (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay after 96 hours’ incubation. Sigmoidal curves were fitted and IC50 values calculated by Prism software.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/123/15/10.1182_blood-2014-01-547943/4/2401f7.jpeg?Expires=1725174615&Signature=FjSxUUULTuvVNHizyM90vNc2I30DP3B2YBP1owPrI2spHyepYh-ixNUAkVet7RCs4a5U8mk3NdpGl7bdp1wGznhjsT6deNHjXuNDyWI3ywsX3g03e2KtI9KuwXWp-UjOiI4nXsLQizt7LGbdu0fXHO67phYC0oZtO2Y7bmeLbWnxpgyvgAL3t246k7NTNmvEkvLKnzmBfRJS3-4Y1zG~6WKtJVuEr3lPONGN7acKbje2Y678Kc9b9qIQh4hpEVeylQ1ioqxnjgqC6WapXgGhKS9GKu9tBSQAbh2gs1Suo4JbLYZZnHPv9PpGMKSxmF0M9CT-2tAAnJsM2~vn8oVjUA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Inhibition of NF-κB sensitizes BCR-ABL1–transformed B lymphoblasts to TKIs. (A) BCR-ABL1/GFP– or BCR-ABL1/IκBαSR–transformed primary B-lymphoid progenitors (4 × 104 cells per well) were incubated with different concentration of imatinib as indicated. Cell viability was determined by MTS assay after 96 hours’ incubation. (B-C) Equal numbers of primary B-lymphoid progenitors transformed by BCR-ABL1/GFP, BCR-ABL1/IKKαKM, or BCR-ABL1/IKKβKM were incubated with different concentration of imatinib (B) or dasatinib (C) as indicated. Cell viability was determined by (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay after 96 hours’ incubation. Sigmoidal curves were fitted and IC50 values calculated by Prism software.
